Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men

CONCLUSIONS: The highest dose level is safe, immunogenic and associated with clinical responses to HPV16-induced lesions. However, as the majority of HGAIN is caused by the other HPV types, further studies should aim at pan-HPV vaccination to prevent or treat HGAIN.PMID:37540563 | DOI:10.1158/1078-0432.CCR-22-3361

Source: Clinical Cancer Research - August 4, 2023 Category: Cancer & Oncology Authors: Karien C M Gosens Sjoerd H van der Burg Marij J P Welters Sanne Boekestijn Nikki M Loof Wim G V Quint Carel J M van Noesel Allard C van der Wal Olivier Richel Wilhelmus J T A Krebber Cornelis J M Melief Henry J C de Vries Jan M Prins Source Type: research